TriVascular Technologies has filed for an IPO. The number of shares that will be offered as well as its pricing terms have yet to be set. The stock will trade on the NASDAQ under the ticker symbol “TRIV.” J.P. Morgan Securities and Credit Suisse Securities are the lead underwriters. Based in Santa Rosa, Calif., TriVascular Technologies is a provider of endovascular aortic repair solutions. Its backers include NEA, Delphi Ventures, MPM Capital, Kearny Venture Partners, Kaiser Permanente Ventures, Rock Springs Capital and Permal Asset Management.
SANTA ROSA, Mar 10, 2014 (GLOBE NEWSWIRE via COMTEX) — via PRWEB – TriVascular Technologies, Inc. (TriVascular), manufacturer of the Ovation Prime(R) Abdominal Stent Graft System, today announced that is has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. TriVascular has applied to list its common stock on the NASDAQ Global Market under the ticker symbol “TRIV.”
J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC are acting as joint book-running managers for the offering. Canaccord Genuity Inc. and Stifel, Nicolaus & Company, Incorporated are acting as co-managers. A registration statement relating to the securities has been filed with the Securities and Exchange Commission, but has not yet become effective. The securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering will be made only by means of a prospectus. Copies of the preliminary prospectus relating to the offering may be obtained, when available, from J.P. Morgan Securities LLC, ℅ Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; or from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, or by telephone at (800) 221-1037, or by email at [email protected]
About TriVascular Technologies, Inc. – TriVascular is a medical device company developing and commercializing innovative technologies to significantly advance minimally invasive treatment of abdominal aortic aneurysms. The company manufactures the Ovation Prime Abdominal Stent Graft System, the lowest profile FDA-approved system, which utilizes a novel, polymer-based sealing mechanism. TriVascular is based in Santa Rosa, California.
Take your pick!
- Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
- VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now.